Literature DB >> 19944072

The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels.

Yoshihisa Ozoe1, Miho Asahi, Fumiyo Ozoe, Kunimitsu Nakahira, Takeshi Mita.   

Abstract

A structurally unique isoxazoline class compound, A1443, exhibits antiparasitic activity against cat fleas and dog ticks comparable to that of the commercial ectoparasiticide fipronil. This isoxazoline compound inhibits specific binding of the gamma-aminobutyric acid (GABA) receptor channel blocker [(3)H]4'-ethynyl-4-n-propylbicycloorthobenzoate (EBOB) to housefly-head membranes, with an IC(50) value of 455pM. In contrast, the IC(50) value in rat-brain membranes is>10muM. To study the mode of action of this isoxazoline, we utilized MdGBCl and MdGluCl cDNAs, which encode the subunits of housefly GABA- and glutamate-gated chloride channels, respectively. Two-electrode voltage clamp electrophysiology was used to confirm that A1443 blocks GABA- and glutamate-induced chloride currents in Xenopus oocytes expressing MdGBCl or MdGluCl channels, with IC(50) values of 5.32 and 79.9 nM, respectively. Blockade by A1443 was observed in A2'S-MdGBCl and S2'A-MdGluCl mutant channels at levels similar to those of the respective wild-types, and houseflies expressing A2'S-MdGBCl channels were as susceptible to A1443 as standard houseflies. These findings indicate that A1443 is a novel and specific blocker of insect ligand-gated chloride channels. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944072     DOI: 10.1016/j.bbrc.2009.11.131

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  51 in total

1.  Efficacy and Pharmacokinetics Evaluation of a Single Oral Dose of Afoxolaner against Sarcoptes scabiei in the Porcine Scabies Model for Human Infestation.

Authors:  Charlotte Bernigaud; Fang Fang; Olivier Chosidow; Jacques Guillot; Katja Fischer; Anne Lespine; Ludwig S Aho; Amanda J Mullins; Berhane Tecle; Andrew Kelly; Jean-François Sutra; Francis Moreau; Thomas Lilin; Frédéric Beugnet; Françoise Botterel
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

2.  GABAA receptor target of tetramethylenedisulfotetramine.

Authors:  Chunqing Zhao; Sung Hee Hwang; Bruce A Buchholz; Timothy S Carpenter; Felice C Lightstone; Felice Lightstone; Jun Yang; Bruce D Hammock; John E Casida
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

3.  New GABA/glutamate receptor target for [³H]isoxazoline insecticide.

Authors:  Pablo García-Reynaga; Chunqing Zhao; Richmond Sarpong; John E Casida
Journal:  Chem Res Toxicol       Date:  2013-03-12       Impact factor: 3.739

4.  Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases.

Authors:  Marie Miglianico; Maarten Eldering; Hannah Slater; Neil Ferguson; Pauline Ambrose; Rosemary S Lees; Karin M J Koolen; Katerina Pruzinova; Magdalena Jancarova; Petr Volf; Constantianus J M Koenraadt; Hans-Peter Duerr; Graham Trevitt; Baiyuan Yang; Arnab K Chatterjee; John Wisler; Angelika Sturm; Teun Bousema; Robert W Sauerwein; Peter G Schultz; Matthew S Tremblay; Koen J Dechering
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-02       Impact factor: 11.205

5.  Evaluation of 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroisoxazole as a novel anti-inflammatory drug candidate.

Authors:  Amanda Roberta Revoredo Vicentino; Vitor Coutinho Carneiro; Anderson de Mendonça Amarante; Claudia Farias Benjamim; Alcino Palermo de Aguiar; Marcelo Rosado Fantappié
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

6.  Safety of fluralaner chewable tablets (Bravecto), a novel systemic antiparasitic drug, in dogs after oral administration.

Authors:  Feli M Walther; Mark J Allan; Rainer K A Roepke; Martin C Nuernberger
Journal:  Parasit Vectors       Date:  2014-03-07       Impact factor: 3.876

7.  Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration.

Authors:  Feli M Walther; Allan J Paul; Mark J Allan; Rainer K A Roepke; Martin C Nuernberger
Journal:  Parasit Vectors       Date:  2014-03-06       Impact factor: 3.876

8.  Pharmacokinetics of fluralaner in dogs following a single oral or intravenous administration.

Authors:  Susanne Kilp; Diana Ramirez; Mark J Allan; Rainer K A Roepke; Martin C Nuernberger
Journal:  Parasit Vectors       Date:  2014-03-07       Impact factor: 3.876

9.  Transcriptome Analysis of the Central and Peripheral Nervous Systems of the Spider Cupiennius salei Reveals Multiple Putative Cys-Loop Ligand Gated Ion Channel Subunits and an Acetylcholine Binding Protein.

Authors:  Päivi H Torkkeli; Hongxia Liu; Andrew S French
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

10.  A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto (fluralaner) against Frontline (fipronil) in flea- and tick-infested dogs.

Authors:  Nadja Rohdich; Rainer K A Roepke; Eva Zschiesche
Journal:  Parasit Vectors       Date:  2014-03-04       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.